Shilpa Medicare has received final USFDA approval for Irinotecan HCL injection to market the same in US. The injection drug will be marketed in the strengths 40 mg/2ml and 100 mg/5ml (20mg/ml) single dose vials.
Irinotecan injection is used in the treatment of patients with metastatic carcinoma of the colon or rectum. According to market estimates, Irinotecan HCL has approximately $18 million potential sales per quarter.
Company Profile : Shilpa Medicare Ltd